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ABSTRACT
SYSTEMIC AND STRENGTH EFFECTS: EXPERIMENTAL
CONCENTRATIONS OF TOPICAL MENTHOL
Lee J. Winchester
August 9, 2010
Menthol has been regularly utilized as a treatment in sports related injuries
for many years, yet little is known about its physiological interactions or its effect
on performance. Our previous study indicates that topically applied menthol may
cause an acute decrease in blood flow and may improve strength capabilities.
The purpose of this study is to examine the effects of two different concentrations
of menthol (3.5% and 10%) on systemic blood flow and strength. 16 subjects
participated in this 4 week study examining blood flow and strength effects after
menthol or control treatment. Results indicate that the 3.5% menthol causes a
significant «.05) decrease in blood flow, and arterial diameter in the treated leg,
and decreased blood flow in the untreated leg. 10% menthol treatment
attenuates the statistically significant increase in blood flow observed with
Control treatment, and significantly decreases arterial diameter in the treated leg.
Results indicate that menthol is capable of suppressing arterial blood flow locally
and systemically.
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CHAPTER 1
INTRODUCTION

Menthol is a heavily researched agent that is found in a variety of different
products. Menthol is typically found as the active ingredient in many pain/burn
relief gels such as Biofreeze, IcyHot, etc. It is a terpene compound that is well
known for its cold or heat sensations as well as its anti-nociceptive and
counterirritant properties [1-3]. As an additive in topical ointments, it is utilized to
soothe the effects of burns, muscle soreness, and even joint pain [1, 3]. This
could playa crucial role in sideline treatment of soft tissue injuries during an
athletic event [4, 5]. If an athlete becomes injured, immediate and effective
treatment must be applied to help sustain their performance capabilities and
prevent further injuries. Although these effects of mentholated ointments are of
common knowledge, detailed mechanisms behind these effects, as well as other
potential effects, are not well established.
With mentholated products being so widely utilized by consumers, one
has to contemplate what impact menthol application has on the individual's
normal physiological functions and physical performance. It has been
demonstrated that menthol may affect the functional ability of certain cellular ion
channels, leading to variations in nerve action potential formation [2, 6-12]. More
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recent research has demonstrated that menthol may even impact blood flow in
the arterial and cutaneous circulation [13-15]. These effects have led our lab to
investigate the impact that menthol may have on performance capabilities.
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CHAPTER 2
LITERATURE REVIEW

Menthol effects regular physiological function in numerous ways. It has
been shown to alter the nervous responses of somatosensory receptors [1-3, 6, 7,
9, 11, 12, 16-18], elicit changes in local and cellular vasoconstrictor responses [8,
10, 13, 15, 19-22], and consequently attenuates the natural physiological
inflammatory cascade [23-25]. Complete mechanisms for each of these
responses are not clearly understood. Nevertheless, recent research has started
to explore menthol's physiological interactions that display these functional
characteristics.
It is now understood that pain is sensed when an effector stimulates
somatosensory receptors. Nociceptors, or pain receptors, trigger an action
potential that stimulates the body to make adjustments either via the spinal cord,
or the upper CNS. This action potential is caused by depolarization of the nerve
cell body through an influx of sodium ions via voltage-operated sodium channels
[2]. Research has shown that the possible anti nociceptive effects of menthol
could be due to the blocking of these sodium channels [2]. Human skeletal
muscle tissue was sampled, and electric stimulus was applied after tissue was
exposed to menthol. At various application strengths, inactivated sodium
channels were measured to determine the effect on depolarization. It was
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demonstrated that the menthol acted as a block of the alpha subunit of voltage
gated sodium channels, therefore causing hyperpolarization of the nervous
membrane and a block in the signal of pain transduction [2].
Another study demonstrates the anti nociceptive effects of menthol by
placing mice on a hotplate and determining pain threshold via observation of
painfully stimulated behavior. This study suggests that the temporary pain relief
from menthol was as effective as morphine for the hot plate test [1]. It is
suggested that menthol selectively activates central K-opioid receptors, which led
to this increase in pain threshold [1].
Menthol has many other noted effects as well, such as temperature
sensations, which are a display of thermoreceptor excitation [6, 7,11, 12, 17,26].
Menthol generates feelings of cold via the transient receptor potential family of
ion channels or (TRP's). TRP's are found throughout the body, but TRPM8,
found mainly within thermosensitive neurons, is known to be commonly effected
by menthol [9, 16, 18, 27-29]. Utilization of calcium imaging techniques has
demonstrated that upon the application of menthol to cloned TRPM8 cells, a
heavy intracellular influx of calcium ions caused depolarization due to the
opening of non-selective calcium permeable cation channels [9, 16, 18, 27-29].
This nervous transduction leads to the thermo-sensation that is recognized from
menthol application. However, menthol is not a direct effector of this calcium
channel stimulation. Phosphatidylinositol 4,5 bisphosphate or PI(4,5)P2 is a
compound that is thought to activate TRPM8 channels, as well as other calcium
cation channels throughout the body. Rohacs et al has demonstrated that
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application of menthol causes a direct sensitization of TRPM8 to the effects of
PI(4,5)P2 [28]. This increase in sensitization is what leads to the excitation
properties of thermosensation via menthol application.
Under certain circumstances, menthol exacerbates cold response to the
point of innocuous cold nociception, typically referred to as cold allodynia [6, 7,
11,12,17,26]. It has been demonstrated that menthol propagates painful cold
stimuli by attenuating the actions of A-delta sensory fibers [12]. A-delta fibers are
responsible for painless cold transmission and their inhibitory effects on C
nociceptor fibers. With menthol present, A-delta fibers become inactive, and C
nociceptors transmit cold pain.
Group III and IV muscle afferents physically correspond to A-delta and C
nociceptor fibers respectively [10]. The vascular pressor response is controlled
in part by the group III and IV afferent fibers. Several studies demonstrate that
menthol's indirect inhibition of the group III afferents attenuate the pressor
response elicited by muscle contraction and cold stimuli [8, 10]. Significant
decreases in mean arterial pressure were observed at 20 minutes post
application [8, 10], with one study showing significant effects even after 40
minutes post treatment [8].
These findings correspond with menthol's ability to cause arterial
vasoconstriction [19-22]. Cold stimulation causes an increased production of
mitochondrial reactive oxygen species (RDS) [20]. RDS have been shown to
activate a Rho A, an inactive protein that binds with GTP and forms Rho kinase
[19]. Rho kinase then translocates a2c adrenergic receptors from the golgi to the
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cell plasma membrane. Norepinephrine activates the a2c adrenergic receptors via
sympathetic reflex of the muscle afferents, creating arterial vasoconstriction [21].
Rho kinase elicits further vasoconstriction by inhibiting actions of myosin light
chain phosphatase in vascular smooth muscle (VSM) cells [19, 30]. This allows
myosin light chain kinase to phosphorylate regulatory myosin light chain proteins,
allowing for sensitization of calcium and contraction of the VSM cells.
Adrenergic stimulation is an established generator of arterial
vasoconstriction [21,22]. However, data suggests that vasoconstriction can still
occur in the absence of adrenergic neurotransmission [22]. Nitric oxide (NO) is a
potent vasodilator of vascular smooth muscle. It is created by nitric oxide
synthase (NOS) and is released from the endothelial cells that line the VSM,
causing vasodilation. Hodges et al. have demonstrated that the cold reflex
inhibits NOS enzyme and other unclear mechanisms downstream in the NO
system; thus, disrupting the normal vascular dilation [22]. Decreased arterial
blood flow has been observed due to reflex vasoconstriction [8, 10, 13, 15, 22,
31], most likely as a result of increased total peripheral resistance [8, 10].
Decreased blood flow to a localized area proves to be beneficial in the
event of an injury [25,31]. Studies suggest that decreased blood flow from
topical cryotherapies, such as menthol, consequently blunt local inflammatory
response [23, 25]. Cryotherapy elicits a hepatic overexpression of interleukin-10
(IL-10), an anti-inflammatory cytokine [23]. Hypothermic tissue response
increases activation of the Janus kinase signaling cascade, resulting in
overproduction of IL-10 via the STAT -3 cytokine transcription pathway [23].
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Normal response to soft tissue injury results in the hepatic transcription of
inflammatory cytokines, such as tumor necrosis factor-a, via nuclear factor kappa
B (NF-KB) separation from its inhibitory protein IKB [24]. However, the resulting
hypothermic stimulation of IL-1 0 overexpression allows for the inhibition of NF-KB
translocation by preventing the phosphorylation of IKB [23]. This mechanism
provides the tissue protective properties of cold induced blood flow reduction.
A study by Hollis et al. directly demonstrates the effects of menthol and ice
on arterial blood flow reduction [13]. Subjects attended two morning trials
approximately one week apart, during which forearm blood flow from the brachial
artery was collected. Blood flow was measured for 15 minutes to serve as a
baseline measure. Blood flow was measured continuously for 5 minutes before
and for 10 minutes after the topical application of either ice or menthol ointment
[13]. The remaining treatment was applied on the second visit. Mean arterial
pressure was measured at baseline and throughout the entire treatment session
to prevent distortions in blood flow due to blood pressure fluctuation.
Hollis et al reported a significant time effect for ice and menthol treatments,
but did not display any significant treatment interactions [13]. It was found that
blood flow had been significantly (p<.05) reduced in both groups from baseline at
60, 120, 180, 240, and 600 seconds post treatment. At 60 seconds the blood flow
was reduced by approximately 43% compared to baseline, and by 24% for the
rest of the testing period [13]. These findings suggest that menthol and ice cause
similar significant reductions in blood flow, indicating that menthol is as effective
as ice for arterial vasoconstriction.
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Despite evidence supporting local arterial vasoconstriction after topical
cryotherapy, some studies demonstrate increases in cutaneous blood flow after
menthol application [12, 14]. Hong and Shellock found that with Eucalyptamint, a
mentholated topical product, individuals displayed a 4 fold increase in cutaneous
blood flow 5 minutes post application, with a slight gradual decrease until 45
minutes post application when compared to baseline [14]. Skin and muscle
temperature were measured via infrared thermometer and 25g thermistor needle,
respectively. Skin temperature was measured every 5 minutes for 45 minutes,
and had an average, significant change of 0.8 degrees C higher than the base
temperature. Muscle temperature was significantly higher at 30 minutes post
application as well [14]. Differences in methodology, such as treatment and
location of blood flow measurement could be accountable for the discrepancies
between data. It is possible that the increase in cutaneous cellular stimulation
could elicit this increased flow, despite decreased flow to the local muscle tissue.
Besides obvious differences in cutaneous and arterial blood flow, Eucalyptamint
has several active ingredients that are not found in the other menthol ointments.
During a previous study, our research team discovered that mentholated
ointment elicits a statistically significant decrease in arterial blood flow, as well as
an practically improved strength measurements [15]. During this study, subjects
attended 3 experimental sessions approximately 1 week apart. Subjects
received at random, either a topical ice pack, Biofreeze, or Control (no
application) conditions applied to the underside portion of the forearm. During
each of the three sessions, blood flow was measured at 5 minute intervals for 20
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minutes via Phillips HOI 5000 Ultrasound Doppler (Seattle, WA). This was
followed by 4 sets of 30 maximal concentric wrist extension/flexions on a Biodex
System 3 dynamometer [15].
Statistical analysis demonstrated that radial arterial blood flow was
markedly decreased after the first 5 minutes of the Biofreeze treatment, followed
by a statistically significant increase in blood flow at 20 minutes, when compared
to control condition [15]. However, treatment with a standard ice pack
demonstrated a gradual decrease in blood flow, with significance occurring at 15
minutes post treatment. These results suggest that a topical menthol product
would be better suited for a situation that required short-term, immediate effects,
such as a slight muscle injury or chronic joint pain, allowing an individual to
experience a rapid recovery [15]. Nevertheless, these results further support the
belief that topical cryotherapy is an effective arterial vasoconstrictor, regardless
of its effects on cutaneous blood flow.
The most interesting findings are the effects that the Biofreeze treatment
had on strength performance. When compared to the ice and control conditions,
Biofreeze elicited a statistically insignificant ( p= .83; p=.79; for flexion and
extension respectively) increase in average peak strength across all 4 sets of
extensions and flexions [15]. During the first set of each Biofreeze trial, flexion
and extension strength were increased by approximately 18% and 14%,
respectively, when compared to Control conditions. Even during the

4th

set, the strength remained elevated by 8.5% and 13% respectively for
flexion/extension [15].
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and final

Although these findings are not statistically significant, increases in
performance upwards of 8.5% may be practically significant in an athletic event.
Due to the rapid increase in force production, these effects would most likely be
due to increased neurological activity, and recent discoveries on the mechanistic
actions of menthol could help support this concept.
A topical neurological strength enhancement product would be a valuable
asset to any individual looking to improve their athletic ability. Due to its rapid
effects, it could be utilized shortly before sprinting, weight lifting, or any other
power related events. Although overall strength enhancement could potentially
be an effect, its already recognized pain relief properties could playa role in
functional capacity as well. Kraemer et al. demonstrates that with the usage of a
cetylated fatty acid - mentholated topical cream, 10 subjects suffering from
arthritic pain in the knee, were able to improve the times of their stair climbing
tests (14.85±6.3s pre; 13.05±5.3s post), as well as their up-and-go tests
(9.37±2.9s pre; 8.22±2.4s post) to statistically significant levels after topical
application 2 times daily for 1 week [3]. Although this is more likely due to pain
alleviation rather than strength enhancement, this study suggests that menthol
may enhance performance by preventing the physiological transduction of the
nociceptive pain sensory pathway.
However, many studies report that many terpene compounds, such as
menthol, are extremely efficient at penetrating human skin, including the dermal
and epidermal layers [32-36]. Terpenes are compounds that are typically derived
from essential plan oils, making them rather lipophilic, which allows for easy
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penetration of cellular membranes [36]. A range of 10 to 100 fold increases in
skin permeation have been observed with the use of topical terpene products
[36]. Menthol, in specific, has been show to be effective at skin penetration [34,
35]. Martin et al. demonstrate that menthol can actually be measured in the
bloodstream (19.0 ± 5.4 ng/mL) after topical patch application, and retains a half
life of approximately 4.7 hours [34]. The penetration effects of topical menthol
suggest that it may even alter intracellular mechanisms of muscle cells.
As the skeletal muscle sarcolemma depolarizes, it stimulates the
dihydropyridine - ryanodine receptor complex of the terminal cisternae, leading
to a release of calcium ions from the sarcoplasmic reticulum into the sarcoplasm
[37-39]. This intracellular influx is what eventually causes the excitationcontraction coupling of muscle tissues. Phosphoinositides are phospholipids that
are involved in this intracellular calcium release and regulation [37-42]. As stated
earlier, menthol has been shown to sensitize TRPM8 calcium channels to
PI(4,5)P 2 , causing channel activation and calcium influx [28]. PI(4,5)P 2 and other
similar phosphoinositides are found in muscle tissues throughout the body,
including skeletal muscle [37-40, 43, 44]. Phosphoinositides are already known
to activate TRP cation channels in pulmonary artery and aortic smooth muscle
cells [40-42]. Menthol application to this muscle tissue evoked significant
increases in intracellular calcium concentration [42]. Sensitization of calcium
channels to these compounds may promote intracellular calcium influx in skeletal
muscle tissue as well, provided menthol is present. This increase in calcium
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could elicit an even greater force of muscle contraction, due to an increase in
excitation-contraction coupling.
An investigation examining the effects of topical menthol ointments, such
as Biofreeze, on maximal muscle contraction could help clarify menthol's impact
on performance. It is common knowledge that some of the strength gains due to
neurological adaptations from training one limb are displayed in the contralateral
limb during times of injury or other disuse. It is possible that the effects of
menthol could display a systemic effect through the same or similar
neuromuscular mechanism. Topical menthol's ability to enter the bloodstream [34]
suggests even greater promise that a systemic effect could occur.
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CHAPTER 3
PURPOSE

The purpose of this study is to determine the systemic and non-systemic
effects of topical Biofreeze application on peak torque production and arterial
blood flow. Heart rate and blood pressure will be measured to help determine
mechanisms for these effects. Since no specific concentration of menthol has
been deemed as the most effective, an experimental Biofreeze compound of
10% menthol and the standard 3.5% menthol Biofreeze will be utilized to
determine dosing effects. It is hypothesized that application of Biofreeze will
cause an increase in peak torque production on the treated limb, and will cause
lesser, yet still significant increases in the peak torque production of the nontreated limb. It is also hypothesized that the increased concentration will lead to
an even greater increase in peak power output.
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CHAPTER 4
METHODS

This study follows a randomized, repeated measures design. 8 male and 8
female subjects, (mean age 24.2 ± 3.0 years), completed this study. Subjects
were apparently healthy individuals, with no pre-existing cardiovascular disorders
or limb injuries that could impact the results of the study, as assessed by a
Medical History Questionnaire. Subjects were asked to participate in four
sessions, approximately 1 week apart. Session 1 lasted approximately 30
minutes, while sessions 2 through 4 lasted approximately 1 hour.
During the first session, all subjects were consented for participation in the
study using an informed consent document approved by the University of
Louisville Institutional Review Board. Once consent was obtained, each subject
was measured for demographic information by completing a demographic data
collection sheet. This demographic sheet was administered at the beginning of
the study and included age, gender, type and duration of exercise engaged in,
and basic physical measurements. Basic physical measurements include the 3
site Jackson-Pollock skin fold measurements and waist to hip ratio.
A familiarization trial was also administered during the first session.
Sample blood flow and strength measurements were demonstrated to the
subjects in order to clarify the procedure. A single blood flow sample was taken

14

on each leg using the Philips HOI 5000 Ultrasound Doppler (Seattle, WA). Blood
Pressure and Heart Rate measures were taken prior to the blood flow measure
with an Omron automatic blood pressure cuff (Omron Healthcare Inc., Illinois).
Subjects received a test run of one set per leg on the Biodex System 3 (Shirley,
NY) dynamometer. No data was collected during the familiarization trial.
A Philips HOI 5000 Ultra Sound Doppler (Seattle, WA) was used to
quantify blood flow measures of the popliteal artery. Subjects were instructed to
lie down in prone position and remain as still as possible on a padded table
during blood flow collection. Using the automatic blood pressure cuff (Om ron
Healthcare Inc., Illinois), heart rate and blood pressure measures were taken and
recorded prior to the first blood flow measurement, and immediately after the
second blood flow measurement. Once identified manually, the Doppler sensor
head was positioned over the artery until the vessel could be accurately
visualized on the device's video screen. The blood flow through the vessel was
averaged over a full plot of arterial pulsations in order to determine the volume
flow (ml/min) and arterial diameter (cm). Recorded arterial pulsations varied due
to variations in subject heart rates. Pain measurements, based on a a to 10 scale
(0 = no pain; 10 = worst pain imaginable), were taken after blood flow
measurements to determine pain sensations elicited by menthol treatment. This
same protocol was repeated on the contralateral leg immediately after successful
completion of the ipsilateral side.
During experimental sessions two through four, one of three randomly
selected experimental applications was applied directly to the Ipsilateral (right)
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thigh, with no treatment being administered to the contralateral (left) leg.
Biofreeze (3.5% menthol), 10% Biofreeze (10% menthol), or control (no
treatment) were the three treatment possibilities selected at random. The
treatment was introduced immediately following baseline data collection. Due to
the nature of the individual products, subjects were unable to be blinded to the
administered treatments. However, subjects were blinded expected outcomes of
the study. A pre-calculated amount of Biofreeze topical ointment was applied to
the entire surface area of the subject's right thigh. A pilot subject was utilized to
determine the quantity of Biofreeze needed to fully saturate their right thigh.
Biofreeze ointment was applied topically 1 mL at a time until the leg was
saturated with the ointment (subject mean = 7.0 ± 1.1 mL). Saturation was
determined by the skins inability to quickly absorb the ointment. The length and
circumference of the thigh were measured and applied to the cylinder surface
area formula. Thigh measurements were taken from each consented subject,
and the quantity of Biofreeze was extrapolated from the known pilot subject data.
The concentrated Biofreeze was administered in a pre-packaged wipe
form. Subjects were instructed to apply the menthol wipes in a clockwise fashion
using even strokes. Wipes were continuously applied until the leg was saturated,
which typically did not require more than 2 wipes total. Subjects were required to
wear gloves during menthol application to avoid absorption into the hands.
During the control condition no treatment was applied to the leg.
Blood flow data was collected on the ipsilateral then contralateral leg
before treatment and 5 minutes after the experimental application. Baseline
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strength data was collected immediately following the baseline blood flow data
collection using a Biodex System 3 dynamometer. The same protocol was
repeated for trials two through four at the 15, 25 and 35 minute data collection
points. A data collection time line for this protocol can be seen in figure 1.
Each subject was seated and appropriately restrained on the Biodex
System 3 dynamometer. The subjects were asked to complete 1 set of 3
maximal voluntary knee extensions and flexions at a rate of 90 degrees per
second. The Biodex System 3 manual recommends speeds of 60 degrees per
second in a clinical setting, and 120 degrees per second for athletes. Since this
study involved the general population, the median speed, 90 degrees per second,
was the speed chosen for the protocol. In a study by Rothstein et aI., four
isokinetic speeds (30, 60, 90, and 120 degrees per second) were tested to
determine applied subject effort and force based on integrated electromyography
(EMG) using an isokinetic dynamometer [45]. Their data demonstrated minimal
differences in EMG activity based on rate isokinetic speed. This demonstrates
that the selected isokinetic speed of 90 degrees per second will have minimal
impact on the results of our peak torque readings. Range of motion was analyzed
for each subject to account for individual variations in flexibility. This assessment
was performed on the right and then the left leg. This same protocol was
repeated for all 4 time trials. The 3 highest peak torque curves for flexion and
extension were recorded to obtain the subject's maximum leg extension and
flexion strength for both the right and left leg. The highest value recorded for
each extension and flexion was then used for analysis of peak torque (N*m).
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Collected data for blood flow and peak power was then analyzed for
statistical significance using SPSS statistical software. Repeated measures
analysis of variance (AN OVA) were calculated to determine the effect of the
various treatments on blood flow and peak torque production over time.
Significant effects were further addressed through LSD post hoc comparisons.
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CHAPTER 5
RESULTS

HEART RATE AND BLOOD PRESSURE
Repeated measures analysis of variance (ANOVA) indicates a significant
(F=15.432, p=.OOO) linear time effect on mean subject heart rate, with no
significant time and treatment interaction present (see table 2). Post Hoc analysis
indicates that the drop in Biofreeze (69.938 ± 3.204, 65.313 ± 2.648) and control
(70.875 ± 3.204, 65.687 ± 2.648) trial heart rates are statistically significant
between the pre and post treatment blood flow measurements. The 10%
Biofreeze treatment demonstrates a decline in mean heart rate, but is not
statistically significant (p>0.05) (see graph 1). No significant time or time and
treatment interactions were observed with systolic blood pressure (F=0.078,
p=0.781; F= 1.189, p=0.314) or diastolic blood pressure (F=0.425, p=0.518;
F=1.198, p=0.311) for any trial.

BLOOD FLOW AND ARTERIAL DIAMETER
A significant time and treatment interaction (F=11.489, p=.OOO) is
observed with blood flow in the treated popliteal artery (table 3). Least
Significant Differences (LSD=16.39) reveals a decrease in blood flow during the
3.5% Biofreeze trial (128.950±10.234; 103.669±1 0.940), while blood flow during
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the control trial (114.625±10.234; 141.025±10.940) significantly increases (table
4). No statistically significant change in blood flow was observed from 10%
Biofreeze trial data when compared to Control or 3.5% Biofreeze treatments.
However, the ability of the 10% Biofreeze treatment to demonstrate a slight,
insignificant decrease in blood flow could be perceived as practically beneficial
since it attenuates the typical blood flow response as displayed by the statistically
significant increase in blood flow observed with the control treatment (graph 2).
Blood flow data in the untreated popliteal artery demonstrates a significant
time*treatment interaction (F=4.755; p=0.013). LSD analysis (LSD=16.8)
indicates that 3.5% Biofreeze treatment results in a significant decline in left
popliteal blood flow, with control trial almost breaching a significant increase
(MD=16.369) (tables 5 and 6). The untreated popliteal artery demonstrates a
similar pattern to the treated limb, with the 10% Biofreeze trial eliciting an
insignificant decline in blood flow, as observed in the treated popliteal artery (see
graph 3).
Statistical analysis suggests that treated popliteal arterial diameter
displayed a statistically significant time and treatment interaction (F=8.062,
p=0.001) (table5). Both 3.5% Biofreeze (.751±.029; .708±.027) and 10%
Biofreeze (.683±.029; .637±.027) treatment groups demonstrate significant
declines in arterial diameter, or vasoconstriction (LSD=0.04). Control trial data
elicits an increase in arterial diameter (.688±.029; .734±.027) which
demonstrates vasodilation (tables 7 and 8, graph 4). No significant changes
were observed in the arterial diameter of the untreated popliteal artery.
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Pain measures taken during the two blood flow trials showed significance
for time (F=15.666, p=O.OOO) and time treatment interactions (F=3.937, p=0.027).
The pairwise comparisons analysis displays a significant mean difference
(MD=.500) in pain, indicating an increase in pain for both 3.5% Biofreeze and
10% Biofreeze trials over time. For the time treatment interaction, Least
Significant Differences (LSD=0.46) suggests that pain sensation increases in
3.5% Biofreeze and 10% Biofreeze groups when compared to control. (Data
displayed in tables 9-11 )

Maximal Torque Production and Perceived Pain
Repeated measures ANOVA reveals no significant time or time treatement
interactions for any part of the Biodex trial. All treatments resulted in similar
trends in peak torque production for Maximal Voluntary Extension and Flexion of
the treated limb (graphs 5 and 6), and for the untreated limb (graphs 7 and 8),
producing insignificant differences.
Perceived pain data was collected for each leg after each completed set
during the four trials to determine how menthol effects pain response to exercise.
No significant changes were observed for perceived pain over time or between
treatments.
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CHAPTER 6
DISCUSSION

The purpose of this study was to investigate the effects of two different
concentrations of menthol (3.5% and 10%) on: a) arterial blood flow in the treated
leg. b) peak torque production in the treated leg. c) arterial blood flow and peak
torque production in the untreated leg to determine if menthol is capable of
producing systemic effects. d) changes in heart rate, blood pressure, and pain
sensation.
The results have produced several major findings. 1) Heart rate was
significantly reduced during Control and 3.5% Biofreeze trials, but not in the 10%
Biofreeze trial. 2) Blood flow to the treated limb was significantly reduced during
3.5% Biofreeze trial and significantly elevated during Control. 3) Blood flow to
the contralateral limb was significantly reduced by 3.5% Biofreeze treatment. 4)
All 3 trials demonstrate significant changes in arterial diameter of the treated limb.
5) Peak torque production was not influenced by treatment for either leg.

HEART RATE
Data collected during the blood flow portion of the protocol demonstrates
mean heart rate reductions for all three trials, with a significant (p<0.05), 10%
decrease in mean heart rate for Control and 6.6 % decrease for 3.5% Biofreeze
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trials. 10% Biofreeze heart rate reduction was not significant, demonstrating a
2.4% decrease. These results are expected given the vast quantity of research
available on heart rate rebound effect after acute bouts of exercise. Some
studies illustrate significant decreases in heart rate and blood pressure after
acute bouts of low oxygen consumption (-30% V0 2 max) exercise [46, 47]. This
supports our findings due to the 3 repetition maximal voluntary resistance bout
that occurred between blood flow data collection pOints. However, this does not
explicate the greater significant decrease observed in Control trial heart rate.
One explanatory mechanism for this result is the increased adrenergic
stimulation due to the sympathetic reflex associated with menthol application [19,
21,22]. Increased sympathetic stimulation, therefore increased heart, would
explain why a lesser rebound effect was observed in the two trials involving
menthol treatment. With this mechanism originating in the skin, it makes sense
that the more 10% Biofreeze displayed a non-significant decrease, unlike the
standard 3.5% Biofreeze product.

BLOOD FLOW AND ARTERIAL DIAMETER
Blood flow and arterial diameter were both Significantly (p<0.05)
decreased, 19.6% and 5.7% respectively, in the treated popliteal artery due to
3.5% Biofreeze treatment. This agrees with the findings of other studies, which
also expressed menthol induced decreases in arterial blood flow [13, 15, 22] and
increased arterial vasoconstriction [19-22]. Previous work demonstrates that
menthol is as effective as ice for decreasing blood flow [13]. Topical menthol and
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ice treatments are known to excite

02C

adrenergic receptors via sympathetic

stimulation [19, 21] and inhibit the effects of the NOS enzyme [22], leading to
arterial vasoconstriction. Some studies have shown that arterial vasoconstriction
elicits decreases in mean arterial pressure for 20 minutes after application due to
increases in total peripheral resistance (TPR) [8, 10]. This is not consistent with
our findings, which indicate no significant changes in blood pressure for any trial
during blood flow analysis.
Control treatment resulted in statistically significant increases in blood flow
and arterial diameter or the treated popliteal artery (23.0% and 6.6%
respectively). This increase in blood flow and arterial diameter can be attributed
to the maximal resistance exercise that occurred between blood flow trials.
Arterial vasodilation normally occurs in response to exercise training, allowing for
increased blood flow. Exercise induced vasodilation occurs due to nitric oxide
release with increasing vascular shear stress [48]. This explains why lack of
treatment resulted in increased arterial diameter and blood flow. Increased
arterial diameter would indicate an overall decrease in TPR, which provides a
larger stroke volume due to increased ventricular filling. Such an increase in
stroke volume further supports why increased flow was observed, despite the
significant decrease in Control heart rate.
No significant effects were observed with blood flow of the ipsilateral limb
due to 10% Biofreeze treatment. Nevertheless, the 10% Biofreeze results did
follow the general trend of the 3.5% Biofreeze trial, with a 8.3% reduction in
blood flow and a statistically significant decrease in arterial diameter of 6.7%. It is
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difficult to explain why a more concentrated menthol product would display lesser
results. Closer examination of the two Biofreeze products could explain this
outcome. The Biofreeze gel (3.5% menthol) and Biofreeze wipes (10% menthol),
contain many of the same compounds. However, the Biofreeze gel contains two
ingredients, propylene glycol and glycerol, that are not found in the wipes.
Studies have shown that propylene glycol and glycerol are very effective at
increasing the absorption rate and permeability of topical products [49-51]. One
study in particular demonstrates that propylene glycol increases the dermal
translocation of hydrogel drugs [49]. This clearly supports why the product
lacking these ingredients is less effective.
In the contralateral artery, 3.5% Biofreeze treatment resulted in a
statistically significant, 14.7% decrease in arterial blood flow. However, no
significant changes in blood flow were found in the contralateral limb for Control
or 10% Biofreeze treatments. Despite the lack of significance, Control and 10%
Biofreeze treatments still displayed similar effects as observed in the treated leg,
with Control group demonstrating a 15.2% increase in blood flow, which almost
breaches statistical significance. 10% Biofreeze treatment elicits a 5.4%
decrease in blood flow, which is similar to the 8.3% observed in the treated limb.
These alterations in arterial blood flow support the concept that the sympathetic
reflex from menthol causes an increase in TPR [8, 10], indicating a systemic
effect of topical menthol application. Although the results are insignificant, 10%
Biofreeze and 3.5% Biofreeze treatments decreased arterial diameter by 3.6%
and 2.1 % respectively, while Control treatment increased arterial diameter by
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2.5%. These results follow the same pattern as the treated limb, but to a lesser
extent, indicating that the systemic effect is relatively mild.

RESTING PAIN RESPONSE
A significant increase in pain rating was observed during blood flow
analysis for the 3.5% Biofreeze and 10% Biofreeze trials over time and when
compared to Control. Menthol is known to elicit sensations of acute cold allodynia
[11] by stimulation of thermal TRP channels [9, 16, 18, 28, 29]. This TRP channel
stimulation creates an inhibitory effect on the A-delta nerve fibers, allowing for
thermal transmission via C nociceptors [6-8, 10-12]. This demonstrates an
increase in innocuous cold pain due to menthol application.

MAXIMAL TORQUE PRODUCTION
Results from the maximal voluntary extension and flexion trials did not
agree with the hypothesized results. There were no significant differences
between any of Biodex trials for any treatment, indicating that topical menthol
products have no effect on peak torque production. These findings agree with our
previous findings that display no stastically significant changes in peak torque
production due to topical Biofreeze applications [15]. However, the treatment
location and strength protocols are very dissimilar, which may be the cause of
the insignificant increases observed previously. The other study applied
Biofreeze treatment directly to the forearm instead of the thigh, and utilized sets
of 30 repetitions with the forearm [15]. The much smaller muscle mass volume,
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or differences in fiber type composition could have provided the observed results
when testing the forearm. Whether menthol could reveal performance
enhancement through its analgesic properties [1-3], allowing a person to feel less
pain during exercise; or through its ability to cause calcium influx by activating
skeletal muscle calcium channels [18, 28, 42], further investigation is necessary
to truly determine its effects on muscular performance.
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CHAPTER 7
CONCLUSION

In conclusion, it is further supported that topical menthol causes a
decrease in arterial blood flow by means of arterial vasoconstriction and
increased total peripheral resistance. Although the results are less profound, it
appears that menthol may actually cause a systemic reduction on blood flow.
This study further supports menthol's actions on increased thermosensation, with
significant increases in observed cold pain. It was also demonstrated that
menthol concentration was not as important as the added ingredients to enhance
its absorption. 3.5% Biofreeze displayed greater significance than 10% Biofreeze
wipes in almost every category. This was likely attributed to the 3.5% Biofreeze's
increased penetration due to its added ingredients, glycerol and propylene glycol.
Menthol application displayed no apparent changes in performance. The
known physiological effects make performance enhancements from topical
menthol seem promising. Due to the nature of our measurements, our study was
subject to human error and variation in subject effort. Therefore, further study is
needed to confirm whether or not menthol impacts muscular performance.
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Figure 1. Time Line of a Single Testing Session Which Includes Three Data
Collection Points

Baseline Data
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- Blood flow
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- Observed Pain

5 Min Data
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35 Min Data
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- Max leg ext/flex

I
25 Min Data
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I
I
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- BioFreeze
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Table 1. Descriptive Statistics

Descnptlve Statlstlcs
Minimum

N

Maximum

Mean

Std. Deviation

Age

16

22.00

35.00

24.1875

2.97139

Height.lN

16

61.25

73.00

66.6094

3.43265

Weight.LBS

16

113.00

221.00

157.5000

34.36083

RestingHR

16

47.00

92.00

66.5000

13.20101

RestingBP.SYS

16

105.00

143.00

121.7500

12.57776

RestingBP.DIA

16

54.00

73.00

66.6250

5.48787

BodyFatPercentage

16

5.90

28.00

17.9437

6.28267

Waist.cm

16

60.00

85.00

72.8125

8.47914

Hips.cm

16

91.00

110.00

98.0625

6.18028

Aerobic Exercise. mi n

16

.00

410.00

200.7375

122.22126

ResistanceExercise. min

16

.00

410.00

150.5125

125.37704

Valid N (listwise)

16

30

Table 2. Significant time effect observed during Biofreeze and Control trials from
baseline measure.
Tests of Within-Subjects Contrasts
Heart Rate: Initial Compared to 5 Minutes Post Application
Source

Time

Type III Sum of
Squares

Mean Square

df

F

Sig.

Time

Linear

341.260

1

341.260

15.432

.000

Time * Treatment

Linear

63.146

2

31.573

1.428

.250

Error(Time)

Linear

995.094

45

22.113
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Graph 1. Heart rate response by treatment. Significant time effect observed
during Control and Biofreeze trials from baseline measure.
* Indicates Significance at .05 alpha level
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Table 3. Right popliteal blood flow response to treatment. Significant
time*treatment effect observed.
Tests of Within-Subjects Contrasts
Blood Flow Right Popliteal Artery
Source

Time

Type III Sum of
Squares

df

Mean Square

Sig.

F

Time

Linear

140.893

1

140.893

.291

.592

Time * Treatment

Linear

11110.721

2

5555.361

11.489

.000

Error(Time)

Linear

21758.311

45

483.518
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Table 4. Right popliteal blood flow response to treatment. Significant
time*treatment effect observed during Biofreeze and Control Trials.
LSD=16.39
4. Treatment * Time
BI 00 d Flow Riglht Popllteal
r Artery
Treatment

Time

95% Confidence Interval
Mean

B

10%
.-

C

Std. Error

Lower Bound

Upper Bound

1

128.950

10.234

108.338

149.562

2

103.669

10.940

81.634

125.703

1

100.913

10.234

80.301

121.524

2

92.525

10.940

70.491

114.559

1

114.625

10.234

94.013

135.237

2

141.025

10.940

118.991

163.059
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Graph 2. Right popliteal arterial blood flow response to treatment. Significant
time*treatment effect observed during Biofreeze and Control trials.
* Indicates Significance at .05 alpha level
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Table 5. Left popliteal blood flow response to treatment. Significant
time*treatment effect observed.
Tests of Within-Subjects Contrasts
Blood Flow Left Popliteal Artery
Source

Time

Type III Sum of
Squares

df

Mean Square

Sig.

F

Time

Linear

138.000

1

138.000

.272

.604

Time * Treatment

Linear

4822.834

2

2411.417

4.755

.013

Error(Time)

Linear

22822.441

45

507.165
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Table 6. Left popliteal blood flow response to treatment. Significant
time*treatment effect observed during Biofreeze trial.
LSD=16.8
4. Treatment * Time

Blood Flow Le t Popliteal Artery
Treatment

95% Confidence Interval

Time
Mean

B

10%
-

C

Std. Error

Lower Bound

Upper Bound

1

121.556

10.523

100.362

142.750

2

103.669

11.096

81.320

126.018

1

104.962

10.523

83.768

126.157

2

99.288

11.096

76.938

121.637

1

107.700

10.523

86.506

128.894

2

124.069

11.096

101.720

146.418

*Control approaching significance with Control Difference of 16.3

37

Graph 3. Left popliteal arterial blood flow response to treatment. Significant
time*treatment effect observed during Biofreeze trial.
* Indicates significance at .05 alpha level.
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Table 7. Right Popliteal Arterial Diameter response to treatment. Significant
time*treatment effect observed.
Tests of Within-Subjects Contrasts
Right Popliteal Arterial Diameter
Source

Time

Type III Sum of
Squares

df

Mean Square

F

Sig.

Time

Linear

.005

1

.005

1.809

.185

Time * Treatment

Linear

.043

2

.021

8.062

.001

Error(Time)

Linear

.120

45

.003
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Table 8. Right Popliteal Arterial Diameter response to treatment. Significant
time*treatment effect observed in all treatments. (p<O.OS)
LSD=.04
4. Treatment * Time
Right Popliteal Arterial Diameter
Treatment

95% Confidence Interval

Time
Mean

B

10%
.-

C

Std. Error

Lower Bound

Upper Bound

1

.751

.029

.693

.808

2

.708

.027

.655

.762

1

.683

.029

.625

.740

2

.637

.027

.583

.690

1

.688

.029

.630

.746

2

.734

.027

.680

.787
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Graph 4. Right popliteal arterial diameter response to treatment. Significant
time*treatment effect observed during all trials.
* Indicates Significance at .05 alpha level
I

Right Popliteal Arterial Diameter
0.76 -,-- - - - - - - - - - - - - - - - - - - - - ,
0.74
_ 0.72

~

E

~

0.7

~E

0.68

...

-

*
~* --

~10%

-

~ Biofreeze

-

C'Cl

is 0.66
0.64

-

0.62 - t - - - - - - - - - - - - r - - - - - - - - - - - - - - i

2
Time

41

Control

Table 9. Pain response to treatment during blood flow data collection. Significant
time and time*treatment effect observed.
Tests of Within-Subjects Contrasts
Perceived Pain From Treatment DurinQ Blood Flow Data Collection
Source

Time

Type III Sum of
Squares

df

Mean Square

F

Sig.

Time

Linear

6.000

1

6.000

15.666

.000

Time * Treatment

Linear

3.016

2

1.508

3.937

.027

Error(Time)

Linear

17.234

45

.383
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Table 10. Pain response to treatment during blood flow data collection.
Significant time and time*treatment effect observed.
Pairwise Comparisons

P
d P am
. D'
unng BI 00 d FI ow Data Co II ectlon
erceive
(I) Time

(J) Time

95% Confidence Interval for
Difference8

Mean
Difference (I-J)
..

1

2

2

1

-.500

.
.500

Std. Error

Sig. 8

Lower Bound

Upper Bound

.126

.000

-.754

-.246

.126

.000

.246

.754

Based on estimated marginal means
*. The mean difference is significant at the .05 level.

a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments).
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Table 11. Pain response to treatment during blood flow data collection.
Significant time and time*treatment effect observed during Biofreeze and 10%
Biofreeze trials. (p~0.05)
LSD=.46
4. Treatment * Time
Perceived Pain Durina Blood Flow Data Collection
Treatment

95% Confidence Interval

Time
Mean

B

10%
.-

C

Std. Error

Lower Bound

Upper Bound

1

.000

.000

.000

.000

2

.781

.219

.341

1.222

1

.000

.000

.000

.000

2

.719

.219

.278

1.159

1

.000

.000

.000

.000

2

1.110E-16

.219

-.441

.441
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Graph 5. Right leg maximal voluntary extension response to treatment. No
Significance observed.
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Graph 6. Right leg maximal voluntary flexion. No significant effects observed.
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Graph 7. Left leg maximal voluntary extension. No significant effects observed.
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Graph 8. Left leg maximal voluntary flexion. No significant effects observed.
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